UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Frontiers in oncology, 2020-01, Vol.9, p.1380-1380

2020

Volltextzugriff (PDF)

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

Clinical cancer research, 2009-05, Vol.15 (10), p.3251-3255

2009

Volltextzugriff (PDF)

Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

Cancer research (Chicago, Ill.), 2008-03, Vol.68 (6), p.2024-2032

2008

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Heat shock proteins: a potential anticancer target

Current drug targets, 2011-12, Vol.12 (14), p.2001-2008

2011

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1885-1893

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.570-576

2008

Volltextzugriff (PDF)

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

Cancer chemotherapy and pharmacology, 2008-04, Vol.61 (4), p.535-548

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Journal of clinical oncology, 2006-02, Vol.24 (4), p.552-562

2006

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2003-01, Vol.21 (1), p.148-157

2003

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2675-2683

2007

Volltextzugriff (PDF)

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

Clinical cancer research, 2005-11, Vol.11 (21), p.7866-7871

2005

Volltextzugriff (PDF)

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Clinical cancer research, 2010-06, Vol.16 (11), p.3044-3056

2010

Volltextzugriff (PDF)

Maximum tolerated dose: clinical endpoint for a bygone era?

Targeted oncology, 2009-04, Vol.4 (2), p.143-147

Takimoto, Chris H.

2009

Volltextzugriff (PDF)

Design, conduct, and interpretation of organ impairment studies in oncology patients

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3509-3510

2006

Volltextzugriff (PDF)

Improving attribution of adverse events in oncology clinical trials

Cancer treatment reviews, 2019-06, Vol.76, p.33-40

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

European journal of cancer (1990), 2009-09, Vol.45, p.436-438

Takimoto, Chris H

2009

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Clinical cancer research, 2003-07, Vol.9 (7), p.2465-2471

2003

Volltextzugriff (PDF)

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Cancer chemotherapy and pharmacology, 2009-03, Vol.63 (4), p.703-709

Takimoto, Chris H

2009

Volltextzugriff (PDF)

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

The oncologist (Dayton, Ohio), 2008-10, Vol.13 (10), p.1043-1045

Takimoto, Chris H.

2008

Volltextzugriff (PDF)

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Clinical cancer research, 2012-11, Vol.18 (22), p.6364-6372

2012

Volltextzugriff (PDF)

Chronomodulated chemotherapy for colorectal cancer: Failing the test of time?

European journal of cancer (1990), 2006-03, Vol.42 (5), p.574-581

Takimoto, Chris H.

2006

Volltextzugriff (PDF)

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Biochemistry (Easton), 1993-05, Vol.32 (18), p.4756-4760

1993

Volltextzugriff (PDF)

Anticancer drug development at the US National Cancer Institute

Cancer chemotherapy and pharmacology, 2003-07, Vol.52, p.S29-S33

TAKIMOTO, Chris H

2003

Volltextzugriff (PDF)

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Clinical cancer research, 2003-07, Vol.9 (7), p.2527-2537

2003

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(95)

Publikationsform

Sprache

Englisch
(104)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(66)
Science & Technology
(61)
Life Sciences & Biomedicine
(60)
Oncology
(49)
Biological And Medical Sciences
(47)
Medical Sciences
(44)
Pharmacology. Drug Treatments
(39)
Antineoplastic Agents
(34)
Female
(34)
Male
(34)
Neoplasms - Drug Therapy
(30)
Middle Aged
(29)
Adult
(27)
Aged
(23)
Chemotherapy
(22)
Dose-Response Relationship, Drug
(15)
Pharmacology & Pharmacy
(15)
Infusions, Intravenous
(14)
Camptothecin - Analogs & Derivatives
(12)
Drug Administration Schedule
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Heat shock proteins: a potential anticancer target

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Maximum tolerated dose: clinical endpoint for a bygone era?

Design, conduct, and interpretation of organ impairment studies in oncology patients

Improving attribution of adverse events in oncology clinical trials

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Chronomodulated chemotherapy for colorectal cancer: Failing the test of time?

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Anticancer drug development at the US National Cancer Institute

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Aktive Filter

Suchergebnisse filtern